å»è¬åå ¬è¡šãããæŽå¯
H1N1ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã¯ãäž»ã«åŒåžåšç³»ã«åœ±é¿ãåãŒãã¹ã€ã³ãã«ãšã³ã¶ãšããŠäžè¬çã«ç¥ãããŠãããŠã€ã«ã¹æ§çŸæ£ãåŒãèµ·ãããŸãã Swine 㯠H1N1 ç·åŒµããã®äŒæã«ãã£ãŠç¹åŸŽä»ããããŸãã H1N1ãã©ã ã®çç¶ã¯ãç±ãå³ãåã®çã¿ã錻氎ãèµ€ã®ç®ãäœçãé çãç²åŽãäžç¢ã§ãã H1N1ã¯ãæ±æããã空æ°ãŸãã¯å°ççãªå ŽæãšãŠã€ã«ã¹ã«ææããæ¥è§Šãä»ããŠåºãããŸãã H1N1ææã¯ãæ°ç®¡æ¯çãèºçãªã©ã®ä»ã®æ ¢æ§åŒåžåšçŸæ£ãæªåãããå¯èœæ§ããããŸãã ãããã¯ã¹ããããŠæã«ã¯åŒåžåšé害ã«ããæ»ã§ãããH1N1ã¯ã¯ãã³ã¯2009幎以æ¥ãH1N1ãã³ãããã¯ã«åãçµãéèŠãªé©æ°ã§ãã åœ... ãã£ãšèŠã
ã³ãã³ããã³Rectalçã¯åžå ŽèŠæš¡ãšäºæž¬ããã©ãã° - 2025 - 20322025幎ïœ2032幎ã«ãããŠãäžçå€§è žããå»è¬ååžå ŽèŠæš¡ã¯ã8.3%ã®ååç©å¹Žéæé·ç(CAGR)ã2025ãã2032幎ãŸã§ã«14.6åç±³ãã«ã«éããèŠèŸŒã¿ã§ããããããã£ãŒã«ã³ãã³ããã³ãªã¯ã¿ã«çè¬ã¯è «çã®æé·ãæå¶ãã転移ãé²ããå¿è匷ãçåãæ¹åããããã«èšèšãããŠããæ²»çè¬ã®åºãç¯å²ãå«ãã§ããŸãã ãããã®è£œåã¯ãEGFRãŸãã¯VEGFä¿¡å·çµè·¯ããããã¯ããæšççæ³ãããã³ç现èã«å¯Ÿããäœã®å ç«ç³»ã掻æ§åããæ¬¡äžä»£å ç«çæ³ãªã©ã®ååŠçæ³è¬ã䌎ããŸãã çµå£ããã³éèå 補å€ã¯ãæè¬ã®æè»æ§ãæäŸããªãã... ãã£ãšèŠã
ã¢ã³ãããã³ãã³åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032äžçã¢ã³ãããã³ãã³åžå ŽèŠæš¡ã¯ã2025幎ãã2032幎ãŸã§ã®USD 1.65åç±³ãã«ã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã®USD 2.78åãã«ã«éãããšäºæ³ãããããããã£ãŒã«ã¢ã³ãããã³ãã³åžå Žã¯è¡ååºã調ç¯ããã®ã«äœ¿çšãããè¡æŒ¿ãŸãã¯çµæãã®æºããåŸãããæ²»çããã³èšºæãããã¯ãã䌎ããŸãã Antithrombinã®æ¿çž®ç©ã¯å 倩æ§ãŸãã¯åŸãããæ¬ é¥ã®æ£è ã«ãæ·±ãéèã®è¡æ çãèºå¡æ çã®ãããªæ¡ä»¶ãé²ãããããŠè¡ç®¡ã®ååºãæãªãããã«ç®¡çãããŸãã åçµä¹Ÿç¥ãããç²ããã³æ³šå°å¯èœãªå ¬åŒã¯ã人éã®è¡æŒ¿ç±æ¥ããã³çµæãã®å€åœ¢ã§å©çš... ãã£ãšèŠã
æ§çã«ééæ§çŸæ£(STD)æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«æ§ææç(STD) æ²»çåžå ŽèŠæš¡ã¯ã2025幎ã«15.7åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«25.4åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®7.3%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«STDã®åŠçœ®ã®åžå Žã¯ã®ãããªäŒæã管çããããšãç®çãšããè¬å€ããã³çç©çãããã¯ãã®åºãã¹ãã¯ãã«ããæã£ãŠããŸã ãã€ããæ¢ æ¯ãæ·ç ãã¯ã©ããžã¢ããã«ãã¹ãHPVã æ²»çã«ã¯ãæçç©è³ªãæãŠã€ã«ã¹ãã¯ã¯ãã³ãããã³å±æè£œå€ãå«ãŸããŸãã 補åã®æ¯èгã¯ãæ°ããæçç©è³ªãé·æéäœçšã®æ³šå°åš... ãã£ãšèŠã
é«ãªã³ã³ããã㢠å»è¬ååžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032äžççãªHyperphosphatemia å»è¬ååžå ŽèŠæš¡ã¯ã2025幎ïœ2032幎ãŸã§ã®9.2%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããUSD 6.7åç±³ãã«ã«éããèŠèŸŒã¿ã§ãããããã£ãŒã«Hyperphosphatemiaã®è¬å€ã¯ç³å°¿ç ãçµãæ ¢æ§ã®è èç (CKD)ã®æ£è ã§äž»ã«é«ããããé£é žå¡©ã®ã¬ãã«ãæžããã®ã«äœ¿çšãããæ²»çè¬ã§ãã ã«ã«ã·ãŠã ç³»ãéã«ã«ã·ãŠã ç³»(ã»ãã©ãŒãã©ã³ã¿ã³ã«ãŒãããŒã)ãé系補å€ãªã©ã®ãªã³é žãã€ã³ãã©ãŒã§æ§æãããŠããŸãã ãããã®è£œåã¯ãèè žç®¡ã®é£å¡©ãçµåããããšã«ãããè¡æµãžã®åžåãé²ããŸãã ... ãã£ãšèŠã
è «çåŠæ é€åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ãªãã³ããžãŒæ é€åžå ŽèŠæš¡ã¯ã2025幎ã®USD 4.3åã§è©äŸ¡ããã2032幎ãŸã§ã®USD 7.6åãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®8.1%ã®ååç©å¹Žéæé·ç(CAGR)ã瀺ããŠããŸãããããã£ãŒã«è «çåŠã®æ é€è£œåã¯ãæ²»çäžããã³æ²»çåŸã®ããæ£è ã®ä»£è¬ãšæ é€ã®å¿ èŠæ§ãæºããããã«èšèšãããå°éçæ é€åŠæ¹ã§ãã ãããã«ã¯ãçµå£ãµããªã¡ã³ããè žé£Œæãããã³ã¿ã³ãã¯è³ªããªã¡ã¬-3èèªé žããã¿ãã³ãããã³æé žåç©è³ªã§åŒ·åãããçµå£æ é€ãœãªã¥ãŒã·ã§ã³ãå«ãŸããŸãã åŠæ¹ã¯ãäœäœéãçèéãããã³å ç«åãç¶æããã®ã«åœ¹ç«... ãã£ãšèŠã
Procalcitonin (PCT)ã¯ãã«ã¢ã³ã®calcitoninã®ãããããåé§äœã§ããããããããã®calcitonin (CT)ã®superfamilyã«å±ããŸãã Procalcitoninã¯14.5 kDaã®æšå®ååéã®116ã¢ããé žã®ãããããã§ãã 3ã€ã®éšåã«åé¢ããããšãã§ããŸãã, ããªãã¡ãèªç¶ã«ã«ãããã³, ã«ã«ãããã³ã«ã«ããã·ã«ãã«ãããããã-1, PCTå°åã®ã¢ããé ž. 1970幎代åé ã«ãã«ããŒã«ã»ããªã¹ãšã¬ããŒãã»Jã»ãããã¹ããProcalcitoninãåããŠåé¡ãããŸããã Procalcitoninã¯ç²ç¶è ºã®C现èããã³èºã®å åæ³çŽ°èã«ãã£ãŠäœã... ãã£ãšèŠã
人工骚åžå Žã¯ã2025幎ã®USD 1.72 Bnã§è©äŸ¡ãããUSD 2.57ã«éãããšäºæ³ããã 2032幎ã«Bnã2025幎ãã2032幎ãŸã§ã®5.9%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºã 骚ç²é¬çã®å¢å€§çã¯ãäºæž¬æé2025-2032äžã®åžå Žã®æé·ã®ããã®éèŠãªãã©ã€ãã§ãã åžå Žã®äž»èŠéžæã«ãã人工骚ã®å¢å€§æ°ãäºæž¬æéã«ããã£ãŠåžå Žæé·ãä¿é²ããããšãæåŸ ãããŠããŸããã°ããŒãã«äººå·¥éªšåžå Žã«é¢ããã¢ããªã¹ãã®æèŠ:äºæž¬æéäžã®åžå Žæé·ãæ¯æŽããäž»èŠãªèŠå ã«ã¯ãåžå Žã§ã®äž»èŠéžæã«ããè²·åã®æ°ãå¢ããŠããŸãã ããšãã°ã2020幎11æã«ã¯ãã°ããŒãã«å»çæ©åšã¡ãŒã«ãŒã®Wright Med... ãã£ãšèŠã
ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãã åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032äžçã®ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãã åžå ŽèŠæš¡ã¯ã2025幎ã®USD 2.18åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã«USD 5.35åãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®13.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«åºåœ¢ãªãªãŽãã¯ã¬ãªãã(ASO)ã¯ãç¹å®ã®ã¡ãã»ã³ãžã£ãŒRNA(mRNA)ã®ã·ãŒã±ã³ã¹ã«çµåããããã«èšèšãããæ žé žã®çãåæéã§ãããã«ãã£ãŠéºäŒåçºçŸã調ç¯ããã ãã®åžå Žã§ã®è£œåã¯ãäž»ã«Duchenneçãžã¹ãããã£ãŒãèé«çèçž®ãç¹å®ã®çãªã©ã®éºäŒçããã³... ãã£ãšèŠã
ç¥çµå€æ§çŸæ£æ²»çåžå Žã¯ç±³ãã«45,127.8ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 56,184.0ã«éãããšäºæ³ãããŸã 2032幎ã®Mnã¯2025幎ãã2032幎ã«ãããŠ3.18%ã®æ··åç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŸãã ç¥çµå€æ§çŸæ£ åžå Žã¯ãç¥çµå€æ§çŸæ£ã®èå»¶ã«äžæããäžçäžã®è(èå)ã®äººå£ã«äžæãã匷ãæé·ãçµéšããŠããŸãã ãŸããå®å šã§å¹æçãªæ²»çè¬ã®éèŠã®å¢å ãšãç¥çµå€æ§çŸæ£ããã³å©çšå¯èœãªæ²»çè¬ã«é¢ãã人ã ã®éã§æèã®å¢å ãåžå Žã®æé·ãé«ããããšãæåŸ ãããŸãã ããããç¥çµå€æ§çŸæ£æ²»ç補åã®å³ããèŠå¶ã¬ã€ãã©ã€ã³ãç¹èš±è©Šéšã¯ãåžå Žã®æé·ã劚ããããšãæåŸ ãã... ãã£ãšèŠã
ãã§ãã«ã¢ã©ãã³ åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«ãã§ãã«ã¢ã©ãã³ åžå ŽèŠæš¡ã¯ã2025幎ã®USD 1.72åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã®USD 2.85åã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®7.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«Phenylalanineãããã¯ãã¯é£ç³§ãè¬å€ããã³äŸçµŠã®äŒæ¥ã®äž»äžéç©ãšããŠäœ¿çšãããèªç¶ãª(L-ãã§ãã«ã¢ã©ãã³)ããã³åæã®åœ¢æ ã§ã¢ããé žãå«ãã§ããŸãã L-ãã§ãã«ã¢ã©ãã³ã¯ãã¿ã³ãã¯è³ªã®ãã«ãã£ã³ã°ãããã¯ãšããŠæ©èœããã¢ã¹ãã«ããŒã ãªã©ã®äººå·¥ç峿ã®ãã¬ã«ã¹ã¿ãŒãšããŠæ©èœããŸã... ãã£ãšèŠã
Nerveä¿®çããã³åçåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ãã2032幎ãŸã§ã®USD 8.4åç±³ãã«ã«çžåœããäžççãªNerveã®ä¿®çããã³åçã®åžå ŽèŠæš¡ãæšå®ããã2032幎ãŸã§ã«USD 14.6åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«ç¥çµä¿®åŸ©ããã³åç補åã¯ãçäœææãç¥çµåºæ¿è£ 眮ãç¥çµæ°Žè·¯ãããã³æå·ããç¥çµéã®å埩ã«åœ¹ç«ã€æé·å åããŒã¹ã®æ²»çæ³ã§æ§æãããŠããŸãã äž»èŠãªè£œåã«ããŽãªã«ã¯ããã€ãªãšã³ãžãã¢ãªã³ã°ç¥çµã¬ã€ãã³ã¹ã³ã³ãžãã(NGC)ãå å·¥ã¢ãœã°ã©ãããããã³è»žåæé·ããµããŒãããåæããªããŒããŒã¹ã®è¶³å Žãå«ãŸããŸãã 黿°åºæ¿è£ 眮ããã³ç¥çµèª¿ç¯ã®æ³šå ¥ã¯ãŸ... ãã£ãšèŠã
ãã³ã¿ãŒçå矀治çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032äžççãªãã³ã¿ãŒã·ã³ãããŒã æ²»çåžå ŽèŠæš¡ã¯ã2025幎ãã2032幎ãŸã§ã®USD 1.27åã§è©äŸ¡ããããšæšå®ãããUSD 2.14åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«ãã³ã¿ãŒçåçŸ€ã®æ²»çã«ã¯ãé µçŽ ä»£æ¿çæ³(ERT)ãéºäŒåæ²»çè¬ãåºè³ªæžå°å€ãç²èå€ç³çII(MPS II)ã®çç¶ã管çããããã«èšèšãããæ¯æçæ³è¬ãå«ãŸããŸãã mainstay 補å㯠iduronate-2-sulfatase é µçŽ ã§ãã idursulfase ããã³ãã®å€ç°äœãªã©ãéæŽ»æ§ãªé µçŽ æŽ»æ§ãå埩ããããã«éèçã«æäžãããŸãã æè¿ã®è£œå驿°ã¯ã... ãã£ãšèŠã
åå®®çã¯åžå ŽèŠæš¡ãšäºæž¬ããã©ãã° - 2025 - 2032ã°ããŒãã«ãŠãã«ãªã³ããè¬åžå ŽèŠæš¡ã¯ã2025幎ãã2032幎ãŸã§ã®USD 1.75åç±³ãã«ã§è©äŸ¡ãããUSD 3.15åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«åå®®çè¬ã«ã¯ãååŠçæ³å€(ã«ã«ããã©ãã³ããã¯ãªã¿ãã»ã«)ããã«ã¢ã³çæ³(ããã²ã¹ãã³ãã¢ããã¿ãŒãŒé»å®³å€)ãæšçå€(ã¬ããããããšãããªã )ãããã³å ç«çæ³(ããããªãºããããã¹ã¿ãªãã)ãå«ãŸããŸãã ãããã®è£œåã¯ãåç¬ãŸãã¯çµã¿åãããŠæ²»çãã ã€ã³ããã¯ã¹ ãããŠä»ã®åå®®çã çµå£ãéèå ããã³æ³šå°å¯èœãªåŠæ¹ã¯ãè¬ã®çš®é¡ããã³æ²»ç段éã«å¿ããŠå©çšã§ããŸãã å€ãã®æ°... ãã£ãšèŠã
é²è å€ å»è¬ååžå Žã¯ã2025幎ã«USD 7.48 Bnã§è©äŸ¡ããã2032幎ã«USD 9.39 Bnã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®3.3%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãã ã°ããŒãã«é²è è¬åžå Žã«é¢ããã¢ããªã¹ãã®æèŠ: é²é£è¬ã¯ãè±æ°Žå€ã®æ²»çãšäºé²ã«åœ¹ç«ã¡ãŸãã®ã§ãææ±è¬ãšããŠãç¥ãããŠããŸãã é²é£è¬ã¯ãäžè¬ã«2ã€ã®ã¿ã€ãã«åé¡ãããŸã:åºã¹ãã¯ãã«ã®æã»ãã·ã§ã³è¬ããã³çã¹ãã¯ãã«ã®æã»ãã·ã§ã³è¬ã ãããŒããŠã§ã€ ã¹ãã¯ãã« antiseizureã®è¬ã¯sizureã®ã¿ã€ãã®åºãç¯å²ããçãã¹ãã¯ãã«ã®antiseizureã®è¬ç©ãäž»ã«çŠç¹ãæ±ããŸ... ãã£ãšèŠã
çåè§£æ§ããªããŒåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ã®USD 1.1åã§ãã°ããŒãã«ãã€ãªã¬ãŸã©ãã«ããªããŒåžå ŽèŠæš¡ãè©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã«2.2åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®10.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«çåè§£æ§ããªããŒã¯ãäœå ã§å®å šã«å£åãããããã«èšèšãããå»çã°ã¬ãŒãã®ææã§ãã 補åã«ã¯ãåžåãããåã«äžæçãªæ§é ãµããŒããæäŸããçž«åãã€ã³ãã©ã³ããã¹ãã³ããããã³è¶³å Žãå«ãŸããŸããé€å»æé ã®å¿ èŠæ§ãæé€ããŸãã ãããã®ããªããŒã¯ãå¶åŸ¡ãããå£åçãçäœé©åæ§ãããã³æŽåœ¢å€ç§ãå¿è¡... ãã£ãšèŠã
ã«ããžãµã«ã³ã æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032äžçã®ã«ããžãµã«ã³ã æ²»çåžå ŽèŠæš¡ã¯ã2025幎ã®USD 580.4çŸäžã§è©äŸ¡ããã2032幎ãŸã§ã®7.8%ã®æ··åç©ã®å¹Žéæé·ç(CAGR)ã2025ãã2032幎ãŸã§æºãããšäºæ³ãããŸãããããã£ãŒã«ã«ããžãµã«ãã®æ²»ç補åã¯ãååŠçæ³å€ãå ç«èª¿ç¯å€ãããã³è «ç墿®ããã³è¡ç®¡åœ¢æãé»å®³ããæšççæ³ãå«ã¿ãŸãã 補åã¯ã泚å°å¯èœãªååŠçæ³ããçµå£å°ååè¬ããã³ã¢ãã¯ããŒãã«æäœãžã®ç¯å²ã¯ãç¹ã«ç å€ã®å¢æ®ãæžããããã«èšèšãããŠããŸãã ãããã®çæ³ã¯ãæ£ç¢ºãªæè¬ãæå°éã®æ¯æ§ãããã³æã¬ãããŠã€ã«ã¹æ²»çãšã®äºææ§ã®ããã«åŠæ¹ãããå šèº«... ãã£ãšèŠã
ææçæ²»çè¬åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ææçã®æ²»ç åžå ŽèŠæš¡ã¯ã2025幎ã«74.8åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«116.5åç±³ãã«ã«éããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã®6.8%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«ææçã®æ²»çè¬ã«ã¯ãæãŠã€ã«ã¹ãæèãæçèè¬ãããã³ç åæ§çç©ãæšçããã³æé€ããããã«èšèšãããæéº»è¬ãå«ãŸããŸãã ãããã®è£œåã¯ã埮çç©ã®ã¬ããªã±ãŒã·ã§ã³ãé»å®³ããããå ç«åå¿ã匷åãããããã¹ã现èã«ç åäœçµåã鲿¢ããããããªã©ãããŸããŸãªã¡ã«ããºã ãéããŠæ©èœããŸãã çŸä»£ã®æ²»çè¬ã¯ãã¢ãã¯ããŒãã«æäœã... ãã£ãšèŠã